Skip to content
Altius – Lifestyle
Author:
Oruka Therapeutics, Inc.
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
September 9, 2026
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
August 24, 2026
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 10, 2026
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
May 28, 2026
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
April 28, 2026
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
April 27, 2026
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
April 27, 2026
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
April 26, 2026